Opportunity Information: Apply for PA 09 199
Apply for PA 09 199
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research.
- This funding opportunity was created on Jun 1, 2009 and posted on Jun 1, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education State governments Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Hispanic serving Institutions Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), released this Funding Opportunity Announcement (FOA) to support research focused on identifying and understanding non-coding (nc) RNAs involved in the earliest stages of cancer development. The core idea is to fund projects that discover and characterize ncRNAs found in preneoplasias (precancerous conditions) and early-stage cancers, with the goal of turning that knowledge into practical tools for public health and clinical care. Specifically, the FOA emphasizes three major outcomes: improving early cancer detection and opportunities for early intervention or prevention, developing ways to predict which preneoplastic lesions are most likely to progress into cancer, and creating methods to reliably distinguish benign lesions from lesions that are truly precancerous.
This opportunity uses the NIH R01 mechanism, meaning it is designed for more mature, hypothesis-driven research projects with a solid scientific premise and a clear plan to generate impactful results. The R01 format typically supports multi-year projects and is suited to teams that already have preliminary data or a well-developed approach for biomarker discovery, validation, and mechanistic characterization. The FOA is explicitly paired with a parallel announcement (PA 09 200) that covers the same scientific scope but uses the R21 exploratory/developmental mechanism, which is generally intended for earlier-stage, higher-risk pilot studies. Applicants would choose between the R01 and R21 depending on the maturity and scale of the proposed work.
Funding under this announcement is described as contingent on the availability of funds, and the announcement does not promise a fixed number of awards. In other words, awards may be made if funds are available and if submitted applications score well in peer review and align with NCI program priorities. The opportunity is categorized as discretionary and uses the grant funding instrument type. The activity areas align with CFDA 93.393 (Cancer Cause and Prevention Research) and 93.394 (Cancer Detection and Diagnosis Research), which reflects the program’s emphasis on both understanding cancer-related biology and translating discoveries into early detection and diagnostic strategies. No cost sharing or matching is required, which reduces barriers for applicants that may not have non-federal funds to contribute.
Eligibility is broad and includes many kinds of research-performing organizations. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status (including those other than universities), for-profit organizations other than small businesses, small businesses, state governments, U.S. territories or possessions, and other entities as clarified in the FOA text. The eligibility list also explicitly includes federal agencies, Hispanic-serving institutions, regional organizations, and non-U.S. entities (foreign organizations). This wide eligibility reflects NIH’s intent to attract strong cancer biology and biomarker research wherever it is conducted, including international collaborations when appropriate.
Administratively, the FOA is identified as PA 09 199, titled "Identifying Non-coding RNA Targets for Cancer Early Detection and Prevention (R01)." It was posted and created on June 1, 2009. The original and final closing date listed is September 7, 2012, with an archive date of October 8, 2012, meaning the announcement is no longer active for new submissions but remains accessible for historical reference. Additional details were provided through the NIH Grants Guide link associated with the FOA. For technical issues accessing the announcement, NIH points applicants to the NIH Office of Extramural Research (OER) webmaster contact (FBOWebmaster@OD.NIH.GOV), which is standard for troubleshooting electronic access and linking problems.
At a practical level, this FOA is about moving ncRNA science closer to real-world early detection and prevention impact. The research it encourages sits at the intersection of molecular discovery (finding ncRNAs associated with early disease), biological interpretation (understanding what those ncRNAs do and why they matter), and translational potential (using them to stratify risk, guide surveillance, or help clinicians tell the difference between benign changes and lesions that warrant intervention). In short, NCI’s goal with this program is to expand the pipeline of ncRNA-based markers and targets that can make cancer easier to catch early, easier to prevent, and easier to triage correctly before it becomes invasive disease.
Frequently Asked Questions (FAQs)
What is this funding opportunity trying to support?
This Funding Opportunity Announcement (FOA) from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), supports research focused on identifying and understanding non-coding (nc) RNAs involved in the earliest stages of cancer development. The emphasis is on discovering and characterizing ncRNAs found in preneoplasias (precancerous conditions) and early-stage cancers, and then translating that knowledge into practical tools for public health and clinical care.
What are the main goals or outcomes NCI is emphasizing?
The FOA highlights three major intended outcomes:
- Improving early cancer detection and creating opportunities for early intervention or prevention.
- Developing ways to predict which preneoplastic lesions are most likely to progress into cancer.
- Creating methods to reliably distinguish benign lesions from lesions that are truly precancerous.
What is the FOA number and title?
The FOA is PA 09 199, titled "Identifying Non-coding RNA Targets for Cancer Early Detection and Prevention (R01)."
Which NIH institute is sponsoring this FOA?
The sponsor is the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH).
What grant mechanism does this announcement use?
This announcement uses the NIH R01 mechanism. The R01 mechanism is typically used for more mature, hypothesis-driven research projects with a solid scientific premise and a clear plan to generate impactful results.
How is an R01 project generally described in this FOA?
In the context described, the R01 mechanism is positioned as suitable for multi-year projects and for teams that already have preliminary data or a well-developed approach for biomarker discovery, validation, and mechanistic characterization.
Is there a related opportunity for earlier-stage or pilot studies?
Yes. The FOA is explicitly paired with a parallel announcement, PA 09 200, covering the same scientific scope but using the R21 exploratory/developmental mechanism. Applicants would choose between the R01 and R21 depending on the maturity and scale of the proposed work.
What is the overall research focus area?
The research focus is on non-coding RNAs linked to the earliest stages of cancer, especially ncRNAs present in preneoplasias and early-stage cancers, and on moving those findings toward early detection, prevention, risk stratification, and clinical decision support (such as differentiating benign from truly precancerous lesions).
What is meant here by "preneoplasias"?
The FOA description uses "preneoplasias" to mean precancerous conditions or preneoplastic lesions, with a particular interest in understanding which lesions progress to cancer and which do not.
What types of impacts are expected from the supported research?
Based on the FOA description, expected impacts include expanding the pipeline of ncRNA-based markers and targets that could make cancer easier to catch early, easier to prevent, and easier to triage correctly before it becomes invasive disease.
Is this a grant or a contract?
This opportunity uses the grant funding instrument type and is categorized as discretionary.
Does the FOA guarantee a certain number of awards?
No. Funding is described as contingent on the availability of funds, and the announcement does not promise a fixed number of awards. Awards may be made if funds are available and if applications score well in peer review and align with NCI program priorities.
Is cost sharing or matching required?
No. The FOA states that no cost sharing or matching is required.
What CFDA program areas are associated with this FOA?
The activity areas align with CFDA 93.393 (Cancer Cause and Prevention Research) and 93.394 (Cancer Detection and Diagnosis Research).
Who is eligible to apply?
Eligibility is broad and includes many types of research-performing organizations. The FOA description lists eligible applicants as including:
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofits with or without 501(c)(3) status (including those other than universities)
- For-profit organizations other than small businesses
- Small businesses
- State governments
- U.S. territories or possessions
- Federal agencies
- Hispanic-serving institutions
- Regional organizations
- Non-U.S. entities (foreign organizations)
- Other entities as clarified in the FOA text
Are foreign (non-U.S.) organizations allowed to apply?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).
Are federal agencies allowed to apply?
Yes. The eligibility list explicitly includes federal agencies.
Is this opportunity still open for new applications?
No. The FOA is no longer active for new submissions. The original and final closing date listed is September 7, 2012, and the archive date is October 8, 2012. It remains accessible for historical reference.
When was this FOA posted?
The FOA was posted and created on June 1, 2009.
Where could applicants find additional details when it was active?
The FOA notes that additional details were provided through the NIH Grants Guide link associated with the announcement.
Who should be contacted for technical problems accessing the announcement?
For technical issues accessing the announcement, NIH points applicants to the NIH Office of Extramural Research (OER) webmaster contact: FBOWebmaster@OD.NIH.GOV.
What is the practical, real-world angle of the research encouraged here?
The FOA frames the work as moving ncRNA science closer to real-world early detection and prevention impact. It encourages research spanning molecular discovery (finding ncRNAs associated with early disease), biological interpretation (understanding what those ncRNAs do and why they matter), and translational potential (using them to stratify risk, guide surveillance, or help clinicians distinguish benign changes from lesions that warrant intervention).
How should an applicant decide between the R01 and the related R21 announcement?
Based on the FOA description, applicants would generally choose the R01 (PA 09 199) for more mature, hypothesis-driven projects with a solid premise and plan, and choose the R21 (PA 09 200) for earlier-stage, exploratory/developmental work intended for higher-risk pilot studies.
Browse more opportunities from the same category: Education Health
Next opportunity: Boating Infrastructure Grant Program Tier II
Previous opportunity: Identifying Non coding RNA Targets for Cancer Early Detection and Prevention (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 199
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 199) also looked into and applied for these:
| Funding Opportunity |
|---|
| The National Drug Abuse Treatment Clinical Trials Network (U10) Apply for RFA DA 10 009 Funding Number: RFA DA 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Bioenergetics, Fatigability, and Activity Limitations in Aging (R21) Apply for PA 09 191 Funding Number: PA 09 191 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Bioenergetics, Fatigability, and Activity Limitations in Aging (R01) Apply for PA 09 190 Funding Number: PA 09 190 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21) Apply for PAR 09 162 Funding Number: PAR 09 162 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership (P20) Apply for PAR 09 201 Funding Number: PAR 09 201 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (F31) Apply for PA 09 208 Funding Number: PA 09 208 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cutting Edge Basic Research Awards (CEBRA) (R21) Apply for PAR 09 222 Funding Number: PAR 09 222 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01) Apply for RFA CA 09 025 Funding Number: RFA CA 09 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Early Detection Research Network Biomarker Developmental Laboratories (U01) Apply for RFA CA 09 017 Funding Number: RFA CA 09 017 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fellows in Nursing Research (F31) Apply for PAR 09 227 Funding Number: PAR 09 227 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanisms Underlying the Links between Psychosocial Stress, Aging, the Brain and the Body (R01) Apply for PA 09 216 Funding Number: PA 09 216 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diet, Epigenetic Events, and Cancer Prevention (R01) Apply for PA 09 234 Funding Number: PA 09 234 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diet, Epigenetic Events, and Cancer Prevention (R21) Apply for PA 09 235 Funding Number: PA 09 235 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01) Apply for PA 09 236 Funding Number: PA 09 236 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21) Apply for PA 09 237 Funding Number: PA 09 237 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21) Apply for PA 09 238 Funding Number: PA 09 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 09 239 Funding Number: PAR 09 239 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Early Detection Research Network Clinical Validation Centers (U01) Apply for RFA CA 09 018 Funding Number: RFA CA 09 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $600,000 |
| The Early Detection Research Network Biomarker Reference Laboratories (U24) Apply for RFA CA 09 019 Funding Number: RFA CA 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Detection Research Network Data Management and Coordinating Center and Statistics and Biomarker Resource Center (U24) Apply for RFA CA 09 020 Funding Number: RFA CA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 199", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.